Scientific exchange · Dr. Yuki Quinn

26 Jan 2026 · Phone · Dr. Yuki Quinn, Osaka University Hospital · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0028—

Capture insight from this engagement

Location: Osaka University Hospital
Therapeutic area: Oncology
Country: Japan
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Brain-metastasis subgroup data
Comparator checkpoint monotherapy

Scientific content used

irAE management guide
PD-L1 testing pathway infographic

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Scientific exchange with thoracic medical oncologist at Osaka University Hospital. Discussed brain-metastasis subgroup data, comparator checkpoint monotherapy.

Insights captured (1)

Capture insight

INS-0004Low
Brain-metastasis subgroup data
Brain-metastasis subgroup data: request for data reported by thoracic medical oncologist (JP).
Action in progress

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 4
Depth of exchange: 3
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0028

Audit history (0)

All create, update and approval events for this record

No audit events in sample data